Senaste nyheterna
Utvalda nyheter
Utvalda nyheter
Lokon Pharma receives FDA Fast Track Designation for LOAd703 for the treatment of Pancreatic Cancer
-
Results from first pancreatic cancer trial using immunostimulatory gene therapy is published in Lancet Oncology
Lokon Pharma and Baylor College of Medicine have published results from their joint trial testing an immunostimulatory gene therapy for patients with pancreatic cancer in the well renowned journal Lancet Oncology. The clinical data shows a 55% response rate and 91% disease control rate in the highest dose cohort which is higher than one would expect from standard chemotherapy treatment.
-
Lokon Pharma Initiates a Collaboration with Affibody to Develop Novel Cancer Therapeutics
Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced a collaboration with Affibody AB to develop a novel therapeutic strategy to treat cancer.
“Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already h -
Lokon Pharma Expands Collaboration with Roche Evaluating LOAd703 Immunostimulatory Gene Cancer Therapy in Combination with Tecentriq® (atezolizumab) into Colorectal Cancer
Uppsala, Sweden, August 28, 2020. Lokon Pharma AB, a leading biotechnology company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced an expansion of its current clinical collaboration with Roche to evaluate LOAd703, Lokon’s immunostimulatory armed gene therapy virus in combination with Tecentriq, Roche’s programm
-
Lokon Pharma Announces Collaboration to Combine LOAd703 Oncolytic Virotherapy with Checkpoint Blockade in Pancreatic Cancer and Melanoma
An agreement between Lokon Pharma and Roche.....
-
First Patient Treated by a Novel Oncolytic Virus Armed with Immune Stimulators
Uppsala, Sweden, January 19, 2017 - The first patient has been treated with LOAd703 at Baylor College of Medicine in Houston, TX. LOAd703 is an immunostimulating oncolytic adenovirus developed by Lokon Pharma. The study is enrolling patients with pancreatic cancer who are not eligible for surgical resection. Patients will receive six intratumoral injections of LOAd703 in combination with standard
Kontakter
-
Angelica Loskog Presskontakt CEO, Prof angelica.loskog@lokonpharma.com
